ADMA Biologics Inc ADMA
9.38
(0.14)
(1.47%)
as of 25 Sep
- Market cap
- $2.1B
- P/E
- 13.0×
Follow ADMA
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
63.17% | 35.56% | 43.30% | 41.90% | |
| 43.67% | 26.40% | 28.13% | 27.19% | ||
ROIC |
23.23% | 25.69% | 29.70% | 29.78% | |
Return on Tangible Assets |
50.39% | 31.80% | 32.90% | 32.55% | |
Average Days of Receivables |
102.85 | 113.35 | 97.26 | 98.49 | |
Free Cash Flow per Share |
0.17 | 0.12 | 0.48 | 0.51 | |
Free Cash Flow |
40.61 | 27.51 | 112.55 | 116.22 | |
Capital Expenditures |
(24.36) | (22.89) | (15.77) | (20.50) | |
Piotroski F-Score |
6.00 | 5.00 | 4.00 | 4.00 | |
| Other line items | |||||
Cash ROIC |
11.36% | 7.86% | 17.62% | 18.40% | |
Accounts Receivable Turnover |
5.20 | 4.90 | 4.33 | 4.13 | |
Accounts Payable Turnover |
11.05 | 10.17 | 9.60 | 5.88 | |
Inventory Turnover |
1.20 | 1.15 | 1.00 | 0.84 | |
Average Days of Payables |
39.62 | 37.81 | 37.94 | 64.04 | |
Days of Inventory on Hand |
324.41 | 346.63 | 410.57 | 483.11 | |
Tax Rate |
0.34 | (0.20) | (0.20) | (0.22) | |
Research and Development Expense of Revenue |
0.77% | 0.93% | 1.28% | 2.25% | |
Selling, General and Administrative Expense of Revenue |
18.71% | 17.95% | 18.48% | 19.28% | |
Share Based Compensation of Revenue |
4.11% | 3.93% | 4.26% | 4.47% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.31 | 0.34 | 0.78 | 0.81 | |
Depreciation/Fixed assets |
0.12 | 0.13 | 0.13 | 0.12 | |
Capex/Depreciation |
(2.84) | (2.64) | (1.85) | (2.47) | |
Revenue per Share |
2.05 | 2.14 | 2.16 | 2.24 | |
Operating CF per Share |
0.27 | 0.21 | 0.54 | 0.60 | |
Capex per Share |
(0.10) | (0.10) | (0.07) | (0.09) | |
Capex to Sales |
0.05 | 0.04 | 0.03 | 0.04 | |
Net Profit Margin |
42.87% | 28.80% | 32.43% | 32.98% |
Columns are period end dates